Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 18/20 | 0.69 |
| ▸ | S1PR1 | P21453 | 13/20 | 0.69 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.60 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16695243 | 0.84 | S1PR5 (0.82) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL565212 | 0.84 | S1PR5 (0.87) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL2925566 | 0.83 | SIGMAR1 (0.60) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL9915003 | 0.83 | S1PR5 (0.91) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL992857 | 0.83 | S1PR5 (0.76) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL13215741 | 0.83 | S1PR5 (0.91) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL13258595 | 0.82 | S1PR1 (0.56) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL3027737 | 0.81 | S1PR5 (1.00) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL3042076 | 0.81 | S1PR1 (0.77) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL31395234 | 0.81 | S1PR5 (0.48) | S1PR5S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | S1PR5 2429/4885S1PR1 1120/4885S1PR3 1860/4885 |
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | S1PR1, S1PR4, S1PR3 | S1PR5 5/4885S1PR1 1/4885S1PR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.